MD20160102A2 - Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei - Google Patents

Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei Download PDF

Info

Publication number
MD20160102A2
MD20160102A2 MDA20160102A MD20160102A MD20160102A2 MD 20160102 A2 MD20160102 A2 MD 20160102A2 MD A20160102 A MDA20160102 A MD A20160102A MD 20160102 A MD20160102 A MD 20160102A MD 20160102 A2 MD20160102 A2 MD 20160102A2
Authority
MD
Moldova
Prior art keywords
chromene
pyridopyrazinediones
tetrahydrocyclopropa
gamma
secretase modulators
Prior art date
Application number
MDA20160102A
Other languages
English (en)
Russian (ru)
Inventor
ЭНД Кристофер Уильям АМ
Джон Майкл Хамфри
Дуглас Скотт Джонсон
Грегори Уэйн КАУФМАН
Мартин Янцзин ПЕТТЕРССОН
Даника Антония РАНКИЦ
Антония Фредерик СТЕПАН
Патрик Роберт Верхоест
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20160102(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of MD20160102A2 publication Critical patent/MD20160102A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sunt dezvăluiţi compuşi cu Formula I şi sărurile farmaceutic acceptabile ale acestoraunde X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y şi z sunt aşa cum sunt definiţi în descriere. Sunt de asemenea dezvăluite compoziţii farmaceutice, metode de tratament, metode de sinteză şi produşi intermediari. Aceşti compuşi au proprietăţi de modulatori ai γ-secretazei şi pot fi utili în tratamentul maladiilor neurodegenerative şi/sau neurologice, aşa ca boala Alzheimer şi sindromul Down.
MDA20160102A 2014-04-01 2015-03-18 Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei MD20160102A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01
PCT/IB2015/051988 WO2015150957A1 (en) 2014-04-01 2015-03-18 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Publications (1)

Publication Number Publication Date
MD20160102A2 true MD20160102A2 (ro) 2017-04-30

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160102A MD20160102A2 (ro) 2014-04-01 2015-03-18 Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei

Country Status (29)

Country Link
US (2) US20150274721A1 (ro)
EP (1) EP3126361B1 (ro)
JP (1) JP6643247B2 (ro)
KR (1) KR101886945B1 (ro)
CN (1) CN106211770B (ro)
AP (1) AP2016009465A0 (ro)
AR (1) AR099874A1 (ro)
AU (1) AU2015242330B2 (ro)
BR (1) BR112016022519A8 (ro)
CA (1) CA2944308A1 (ro)
CL (1) CL2016002422A1 (ro)
CR (1) CR20160454A (ro)
CU (1) CU20160140A7 (ro)
DK (1) DK3126361T3 (ro)
DO (1) DOP2016000266A (ro)
EA (1) EA031419B1 (ro)
EC (1) ECSP16078289A (ro)
ES (1) ES2759277T3 (ro)
IL (1) IL248154B (ro)
MD (1) MD20160102A2 (ro)
MX (1) MX369074B (ro)
NI (1) NI201600149A (ro)
PE (1) PE20161364A1 (ro)
PH (1) PH12016501864A1 (ro)
SG (1) SG11201607465UA (ro)
TW (1) TWI568733B (ro)
UY (1) UY36054A (ro)
WO (1) WO2015150957A1 (ro)
ZA (1) ZA201606252B (ro)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
MX368391B (es) * 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
EP3849979A1 (en) 2018-09-12 2021-07-21 Novartis AG Antiviral pyridopyrazinedione compounds
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN113543852A (zh) 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
TW202535873A (zh) 2019-09-26 2025-09-16 瑞士商諾華公司 抗病毒吡唑并吡啶酮化合物
JP2025535295A (ja) 2022-10-18 2025-10-24 ファイザー・インク パタチン様ホスホリパーゼドメイン含有タンパク質３（ｐｎｐｌａ３）修飾因子
EP4604955A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CA2286305A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
JP4708675B2 (ja) 2000-11-03 2011-06-22 プロテオテック・インコーポレーテッド ウンカリア・トメントーサおよび関連植物からアミロイド阻害化合物を単離する方法ならびに単離した化合物の使用
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
NZ534466A (en) * 2002-02-28 2006-04-28 Sanofi Aventis Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl - 6,7,8,9- tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP2006527756A (ja) 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク Ｎｋ１拮抗薬
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
JP2007519707A (ja) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク ヒスタミン−３受容体モジュレーター
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
SG190665A1 (en) 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
DK1881985T3 (da) 2005-05-12 2011-02-14 Pfizer Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
ES2354569T3 (es) 2005-06-22 2011-03-16 Pfizer Products Inc. Antagonistas del receptor de histamina-3.
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
EP2013208B1 (en) 2006-04-21 2011-06-22 Pfizer Products Inc. Pyridin[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
SI2124933T1 (sl) 2007-01-22 2012-12-31 Pfizer Products Inc. Tosilatna sol terapevtske spojine in farmacevtski sestavi tega
WO2010047990A1 (en) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic m1 receptor positive allosteric modulators
ES2602794T3 (es) * 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
MX355164B (es) * 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2014206834B2 (en) * 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
CA2925743C (en) * 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators

Also Published As

Publication number Publication date
AU2015242330B2 (en) 2017-08-17
EA201600619A1 (ru) 2017-03-31
IL248154B (en) 2020-09-30
MX369074B (es) 2019-10-28
KR101886945B1 (ko) 2018-08-08
DOP2016000266A (es) 2016-11-15
CR20160454A (es) 2016-12-06
HK1231481A1 (zh) 2017-12-22
SG11201607465UA (en) 2016-10-28
BR112016022519A8 (pt) 2018-03-06
JP6643247B2 (ja) 2020-02-12
EA031419B1 (ru) 2018-12-28
AP2016009465A0 (en) 2016-09-30
JP2017512803A (ja) 2017-05-25
UY36054A (es) 2015-10-30
AU2015242330A1 (en) 2016-09-22
PH12016501864A1 (en) 2016-12-19
WO2015150957A1 (en) 2015-10-08
US20150274721A1 (en) 2015-10-01
EP3126361B1 (en) 2019-11-06
PE20161364A1 (es) 2016-12-25
DK3126361T3 (da) 2020-01-02
ZA201606252B (en) 2018-05-30
TWI568733B (zh) 2017-02-01
CN106211770A (zh) 2016-12-07
AR099874A1 (es) 2016-08-24
ES2759277T3 (es) 2020-05-08
CL2016002422A1 (es) 2017-02-03
MX2016012904A (es) 2016-12-07
EP3126361A1 (en) 2017-02-08
TW201540716A (zh) 2015-11-01
CA2944308A1 (en) 2015-10-08
IL248154A0 (en) 2016-11-30
CN106211770B (zh) 2018-02-06
CU20160140A7 (es) 2017-02-02
NI201600149A (es) 2016-11-18
US20170166566A1 (en) 2017-06-15
KR20160137635A (ko) 2016-11-30
ECSP16078289A (es) 2017-02-24
BR112016022519A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
MD20160102A2 (ro) Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
MX2021008583A (es) Composiciones para el tratamiento de trastornos del snc.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP4464317A3 (en) Compounds and compositions and uses thereof
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MY191352A (en) Aldosterone synthase inhibitors
PH12017500595A1 (en) Aldosterone synthase inhibitors
PH12017501369A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
MX2016008968A (es) Compuestos organicos.
PH12017501134A1 (en) Fumagillol derivatives
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
IN2013MU03838A (ro)

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)